{"id":3698,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/aripiprazole-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"aripiprazole-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/aripiprazole-txt\/","title":{"rendered":"Aripiprazole.txt"},"content":{"rendered":"

Aripiprazole<\/h1>\n

CLINICAL USE <\/H3>
\nAtypical antipsychotic for the treatment of
\nschizophrenia
\n

DOSE IN NORMAL RENAL FUNCTION <\/H3>
\n10\u201330 mg daily
\n

PHARMACOKINETICS <\/H3>
\n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n448.4\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n>99\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n<1\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n4.9\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n75 (146 in poor
    \nmetabolisers)\/
    \nUnchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • HDF\/high flux &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions\n

    with tramadol; enhanced hypotensive and
    \nsedative effects with opioids
    \nAntihypertensives: may enhance <\/p>\n

    antihypertensive effect<\/p>\n

  • Alcohol and other CNS drugs: increased\n

    sedation and other related side effects<\/p>\n

  • Anti-arrhythmics: increased risk of\n

    ventricular arrhythmias with anti-
    \narrhythmics that prolong the QT interval<\/p>\n

  • Antibacterials: concentration possibly\n

    reduced by rifabutin and rifampicin \u2013
    \nincrease dose of aripiprazole<\/p>\n

  • Antidepressants: fluoxetine and paroxetine\n

    possibly inhibit metabolism \u2013 reduce dose
    \nof aripiprazole; concentration possibly
    \nreduced by St John\u2019s wort \u2013 increase
    \naripiprazole dose; increased concentration
    \nof tricyclics<\/p>\n

  • Anti-epileptics: antagonises anticonvulsant\n

    effect; concentration reduced by
    \ncarbamazepine and possibly reduced by
    \nphenytoin, phenobarbital and primidone \u2013
    \nincrease dose of aripiprazole
    \nAntifungals: metabolism inhibited by <\/p>\n

    ketoconazole and possibly by itraconazole
    \n reduce dose of aripiprazole<\/p>\n

  • Antimalarials: avoid concomitant use with\n

    artemether\/lumefantrine<\/p>\n

  • Antivirals: metabolism possibly inhibited\n

    by amprenavir, atazanavir, indinavir,
    \nlopinavir, nelfinavir, ritonavir and
    \nsaquinavir \u2013 reduce dose of aripiprazole;
    \nconcentration possibly reduced by
    \nefavirenz and nevirapine \u2013 increase dose
    \nof aripiprazole<\/p>\n

  • Anxiolytics and hypnotics: increased\n

    sedative effects
    \nS<\/p>\n

  • ibutramine: increased risk of CNS\n

    toxicity \u2013 avoid concomitant use
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4>
    \nHepatic metabolism and elimination<\/p>\n

    Can cause QT prolongation<\/p>\n","protected":false},"excerpt":{"rendered":"

    Aripiprazole CLINICAL USE Atypical antipsychotic for the treatment of schizophrenia<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3698","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3698"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3698\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}